Aroa Biosurgery (ASX:ARX) ROCE %: 12.93% (As of Mar. 2026)


ASX:ARX Aroa Biosurgery Ltd ASX:ARX
62 GF Score
Price A$0.59
GF Value A$0.80
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Aroa Biosurgery ROCE %?

Aroa Biosurgery ASX:ARX +0.85% 62 ROCE % is 12.93% as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aroa Biosurgery's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.93%.

Aroa Biosurgery  (ASX:ARX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aroa Biosurgery ROCE % Related Terms

Aroa Biosurgery ROCE % Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery ROCE % Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial -7.94 -0.35 -8.63 -2.02 6.28

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.85 -2.84 -1.21 -0.13 12.93
ASX:ARX
62GF Score
Aroa Biosurgery Ltd ASX:ARX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery ROCE % Calculation

Aroa Biosurgery's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=5.545/( ( (98.939 - 9.363) + (100.604 - 13.516) )/ 2 )
=5.545/( (89.576+87.088)/ 2 )
=5.545/88.332
=6.28 %

Aroa Biosurgery's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=11.204/( ( (95.301 - 9.148) + (100.604 - 13.516) )/ 2 )
=11.204/( ( 86.153 + 87.088 )/ 2 )
=11.204/86.6205
=12.93 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.93% mean?
Aroa Biosurgery (ASX:ARX) has a ROCE % of 12.93% as of Mar. 2026.
Is Aroa Biosurgery's ROCE % too high?
Aroa Biosurgery's current ROCE % is 12.93%. The Medical Devices & Instruments industry median ROCE % is 2.23. Aroa Biosurgery's value of 12.93% is 479.8% above this industry median. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's ROCE % compare to ABT and SYK?
Aroa Biosurgery's ROCE % of 12.93% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Aroa Biosurgery's value of 12.93% is 479.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current ROCE % of 12.93% is 479.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current ROCE % is 12.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current ROCE % is 12.93% and 479.8% above the Medical Devices & Instruments industry median of 2.23. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current ROCE % is 12.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for ASX:ARX:

  • ROCE %: 12.93%
  • GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
  • GF Score™: 62/100 with 2 warning signs
  • Industry Position: 479.8% above the Medical Devices & Instruments median

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score

Get the complete analysis for ASX:ARX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.59
Price
A$0.80
GF Value